**Kisspeptin+ 2021 Abstract Submission**

* Abstract submission deadline: **Sunday, March 28, 10pm EST.**
* Submission limit: each lab can submit a maximum of 3 abstracts for consideration.
* All abstracts will be reviewed; only 24 abstracts will be selected for presentation (all 10-minute talks).
* Presenting author must be either a trainee (undergraduate, graduate, postdoc, fellow) or a junior investigator (within 10 years of terminal degree and/or 6 years of starting faculty position)
* Abstracts will be judged solely on academic excellence. However, we will take into account inclusivity for participation from different labs (see above), countries and other aspects of diversity to ensure we have a balanced and inclusive program which is scientifically excellent.

**Abstract Submission Process:**

* Email the abstract as a MS Word file attachment (not a pdf) to admin@kisspeptin2021.com
* Also attach the Diversity, Equity and Inclusion Survey (see last page here) as a separate file in the same email that you submit the abstract.
* Make the email Subject line: “Abstract: [Presenting author’s first and last name]”
	+ *Example Subject line:* Abstract: Maria Delgado
* Make sure the format and style of the abstract conforms to the guidelines below

**Abstract Formatting Guidelines (required)**

* Text formatting: Arial font, size 11, single spaced, alignment = justify
* Title: **ALL CAPITALS, bold text**
* Title: Limit 25 words
* Authors: First name Middle initial. Last name.
	+ *Example:* Jennifer A. Smith
* Underline presenting author
* Affiliation: Department and Institution, City, Country
* Abstract body: **word limit of 300 words** (not including Title, Authors, Affiliation)
* See next page for example of properly formatted abstract

*Example abstract with proper formatting and word limits:*

**EFFECTS OF KISSPEPTIN ON HORMONE SECRETION PATTERNS, BEHAVIOR, AND ENERGY BALANCE IN FEMALE TRANSGENIC GOATS**

Jennifer A. Smith, Tony G. Wynn, John Z. Staff, and Gru P. Leader

Department of Neuroscience, University of Washington, Seattle, WA, USA

Kisspeptin was first discovered as a reproductive neuropeptide in 2003. Work from multiple labs soon demonstrated that kisspeptin strongly activates GnRH neurons to cause LH and FSH secretion from the pituitary. This role in reproduction was supported by finding sin humans and animal models that genetic mutants in the kisspeptin gene (*Kiss1*) cause hypogonadism and infertility. Whether kisspeptin also alters secretion of other hormones relating to reproduction or metabolism is only starting to be studied. Here we used a new transgenic goat model in which kisspeptin neuron activation could be controlled with a designer drug administered in jelly beans. We used this new model to test whether kisspeptin cell activation causes changes in the levels of a number of different hormones or if it alters body weight and feeding. We found that…. kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin. kisspeptin kisspeptin kisspeptin kisspeptin kisspeptin. In conclusion, we report for the first time, that along with robust increases in GnRH and LH secretion after kisspeptin neuron activation, there are also unexpected increases in several other hormones along with several surprising behavioral changes. Whether these alterations are due to kisspeptin-induced increases in gonadal steroid hormones or specific flavors of the jelly beans remains to be tested.

**Diversity, Equity, and Inclusion Survey (*Optional; submit with abstract as a separate file)***

The Organizing Committee is committed to having a diverse group of plenary and trainee speakers for this conference. The answers to the following questions will provide data regarding diversity of individuals submitting abstracts for research presentations. The answers to these questions are completely OPTIONAL. We recognize that individuals may not be comfortable answering these questions and have provided an option to provide a more general response if desired.

All responses will remain CONFIDENTIAL and will only be seen by the abstract selection committee.

**Applicant Name:**

1. **WHAT IS YOUR RACIAL OR ETHNIC IDENTIFICATION? (SELECT ALL THAT APPLY):**

[ ]  AMERICAN INDIAN OR ALASKA NATIVE

[ ]  ASIAN

[ ]  BLACK OR AFRICAN AMERICAN

[ ]  NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER

[ ]  HISPANIC OR LATINO OR SPANISH ORIGIN

[ ]  WHITE

[ ]  OTHER

[ ]  PREFER NOT TO ANSWER

1. **WITH WHICH GENDER IDENTITY DO YOU MOST IDENTIFY?**

[ ]  FEMALE

[ ]  MALE

[ ]  TRANSGENDER FEMALE

[ ]  TRANSGENDER MALE

[ ]  NON-BINARY/NON-CONFORMING

[ ]  NOT LISTED

[ ]  PREFER NOT TO ANSWER

1. **DO YOU IDENTIFY AS A MEMBER OF THE LGBTQ+ COMMUNITY?**

[ ]  YES

[ ]  NO

[ ]  PREFER NOT TO ANSWER

1. **ARE/WERE YOU CONSIDERED A FIRST-GENERATION STUDENT (A STUDENT WHOSE**

 **PARENT(S)/LEGAL GUARDIAN(S) DID NOT COMPLETE A 4-YEAR COLLEGE DEGREE)?**

[ ]  YES

[ ]  NO

[ ]  PREFER NOT TO ANSWER

1. **HAVE YOU BEEN DIAGNOSED WITH A DISABILITY OR AN IMPAIRMENT (SENSORY,**

 **MOTOR, LEARNING, OR OTHER)?**

[ ]  YES

[ ]  NO

[ ]  PREFER NOT TO ANSWER

Please provide any additional comments here: